Oxbow Advisors Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
VBIL
Vanguard 0-3 Month Treasury Bill ETF
VBIL
|
+$157M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$6.72M |
| 3 |
Intuit
INTU
|
+$6.24M |
| 4 |
Workday
WDAY
|
+$6.11M |
| 5 |
Gildan
GIL
|
+$4.72M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
TBIL
F/m US Treasury 3 Month Bill Fund
TBIL
|
+$101M |
| 2 |
iShares Treasury Floating Rate Bond ETF
TFLO
|
+$10.3M |
| 3 |
Elevance Health
ELV
|
+$4.86M |
| 4 |
Teekay Tankers
TNK
|
+$4.07M |
| 5 |
Frontline
FRO
|
+$3.67M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Energy | 15.88% |
| 2 | Materials | 11.52% |
| 3 | Technology | 10.82% |
| 4 | Healthcare | 7.16% |
| 5 | Financials | 6.65% |
Similar funds
Oxbow Advisors's Q3 2025 Portfolio in Review
As of Q3 2025, Oxbow Advisors held 232 positions worth $1.08B, up 18% from $915M the previous quarter. Its ten largest holdings account for 42% of the portfolio.
Oxbow Advisors deployed $87M of net new capital in Q3 2025, opening 23 new positions and adding to 69 existing holdings. Its largest new stake was Vanguard 0-3 Month Treasury Bill ETF: 2,079,988 shares worth $157M.
By sector, the portfolio is most concentrated in Energy at 16% of assets, down from 19% a quarter earlier, followed by Materials and Technology.
On the sell side, the largest reduction was F/m US Treasury 3 Month Bill Fund, an estimated $101M trimmed.
- Oxbow Advisors's largest Q3 2025 buy was Vanguard 0-3 Month Treasury Bill ETF: 2,079,988 shares worth $157M.
- Oxbow Advisors added most to Zoetis in Q3 2025, an estimated $3.73M increase.
- Oxbow Advisors's biggest Q3 2025 reduction was F/m US Treasury 3 Month Bill Fund, cutting an estimated $101M.
- Oxbow Advisors fully exited Elevance Health in Q3 2025, selling an estimated $4.86M.
- Oxbow Advisors's ten largest holdings make up 42% of its $1.08B portfolio in Q3 2025.
- Oxbow Advisors opened 23 new positions and closed 9 in Q3 2025.
- Oxbow Advisors's portfolio value rose 18% quarter-over-quarter to $1.08B.
Based on Oxbow Advisors's 13F filing for Q3 2025, filed 31 Oct 2025.